Glenn J
Rev Infect Dis. 1981 Nov-Dec;3(6):1151-78. doi: 10.1093/clinids/3.6.1151.
This collective review of the literature concerns posttransplantation cytomegalovirus (CMV) infections. In the author's view, patients without previous CMV infection are most often infected by viruses transmitted with the transplanted kidney, whereas patients with prior infections can be infected either from this source or by reactivation of latent CMV. Many posttransplantation CMV infections are asymptomatic or yield only mild systemic effects. A few patients suffer life-threatening disease. However, CMV infections might adversely affect survival of both graft and patient by contributing to graft rejection, weakening the graft recipient's immunity, or by other, more direct, means. Currently, there is no effective, specific treatment of these infections. It is predicted that CMV infections will cease to be a problem only when the means are found to specifically block transplantation immunity, thereby eliminating the need for systemic immunosuppression and eliminating low-level host-vs.-graft responses.
这篇文献综述关注移植后巨细胞病毒(CMV)感染。作者认为,既往未感染CMV的患者大多被随移植肾传播的病毒感染,而既往有感染的患者可能从该来源感染,也可能因潜伏CMV的重新激活而感染。许多移植后CMV感染无症状或仅产生轻微的全身影响。少数患者会罹患危及生命的疾病。然而,CMV感染可能通过导致移植排斥、削弱移植受者的免疫力或通过其他更直接的方式,对移植物和患者的存活产生不利影响。目前,尚无针对这些感染的有效、特异性治疗方法。预计只有当找到特异性阻断移植免疫的方法,从而消除全身免疫抑制的需求并消除低水平的宿主对移植物反应时,CMV感染才不再成为问题。